News & Updates

Show Multimedia Only

Camrelizumab plus chemo sets new benchmark in NPC

06 May 2026 by

A secondary analysis of the phase III CAPTAIN-1st trial shows a significant overall survival (OS) benefit when camrelizumab is added to gemcitabine and cisplatin (GC) for the first-line (1L) treatment of recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).

Camrelizumab plus chemo sets new benchmark in NPC

06 May 2026

First HK consensus statement on use of Alzheimer’s disease biomarkers and anti-amyloid therapies

06 May 2026 by

In response to increasing need for accurate diagnosis of Alzheimer’s disease (AD) pathology with the availability of anti-amyloid therapies (AATs), a 20-member expert panel in Hong Kong has formulated the first multispecialty consensus recommendations to provide practical locally-tailored guidance for healthcare practitioners on the use of imaging and biomarkers for AD diagnosis and AATs.

First HK consensus statement on use of Alzheimer’s disease biomarkers and anti-amyloid therapies

06 May 2026

Severe malarial anaemia & cerebral malaria in children linked to lasting cognitive and academic deficits

06 May 2026 by

Survivors of early-childhood cerebral malaria or severe malarial anaemia may experience persistent deficits in overall cognitive ability and mathematics achievement up to 15 years after the acute episode, an African study has found.

Severe malarial anaemia & cerebral malaria in children linked to lasting cognitive and academic deficits

06 May 2026

Weight-loss outcomes in Asians with high BMI better with cagrilintide–semaglutide vs semaglutide

05 May 2026 by

Individuals with overweight or obesity in East Asia shed more weight following treatment with the fixed-dose combination of cagrilintide plus semaglutide than with semaglutide alone, as shown in the phase 3a REDEFINE 5 trial.

Weight-loss outcomes in Asians with high BMI better with cagrilintide–semaglutide vs semaglutide

05 May 2026

ACEi/ARBs may prevent death, kidney events in older adults after dialysis, but with caveat

05 May 2026

The use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) appears to reduce the risk of all-cause mortality and major adverse kidney events (MAKE) in very old adults who underwent dialysis for acute kidney injury (AKI), suggests a study.

ACEi/ARBs may prevent death, kidney events in older adults after dialysis, but with caveat

05 May 2026

Ipilimumab plus nivolumab prolongs survival in melanoma with brain metastases

05 May 2026 by

Treatment with ipilimumab plus nivolumab improves long-term survival in melanoma patients with asymptomatic brain metastases, according to the results of the NIBIT-M2 trial presented at AACR 2026.

Ipilimumab plus nivolumab prolongs survival in melanoma with brain metastases

05 May 2026

Zibotentan-dapagliflozin combo safe in patients with compensated cirrhosis

05 May 2026

Combination treatment with zibotentan and dapagliflozin results in a favourable safety profile and good tolerability in patients with compensated cirrhosis, but its effect on hepatic venous pressure gradient (HVPG) is inconclusive, a study has shown.

Zibotentan-dapagliflozin combo safe in patients with compensated cirrhosis

05 May 2026

First-time seizures a warning signal for cancers

05 May 2026

First-time seizures appear to be associated with increased short-term and long-term risks of cancer, according to a population-based cohort study.

First-time seizures a warning signal for cancers

05 May 2026

Asian study: Tumour multiplicity in ICC associated with inferior OS

05 May 2026 by

In patients with intrahepatic cholangiocarcinoma (ICC), tumour multiplicity – particularly the presence of ≥4 tumours – is associated with inferior overall survival (OS), a study conducted in Hong Kong, Seoul and Shanghai has shown.

Asian study: Tumour multiplicity in ICC associated with inferior OS

05 May 2026

Romiplostim for chemo-induced thrombocytopenia delivers in phase 3 trial

04 May 2026 by

The thrombopoietin-receptor agonist romiplostim helps mitigate chemotherapy-induced thrombocytopenia, reducing related treatment modifications in patients with gastrointestinal cancers, as shown in the landmark phase III RECITE trial.

Romiplostim for chemo-induced thrombocytopenia delivers in phase 3 trial

04 May 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Camrelizumab plus chemo sets new benchmark in NPC

Camrelizumab plus chemo sets new benchmark in NPC

First HK consensus statement on use of Alzheimer’s disease biomarkers and anti-amyloid therapies

First HK consensus statement on use of Alzheimer’s disease biomarkers and anti-amyloid therapies

Severe malarial anaemia & cerebral malaria in children linked to lasting cognitive and academic deficits

Severe malarial anaemia & cerebral malaria in children linked to lasting cognitive and academic deficits

Weight-loss outcomes in Asians with high BMI better with cagrilintide–semaglutide vs semaglutide

Weight-loss outcomes in Asians with high BMI better with cagrilintide–semaglutide vs semaglutide

ACEi/ARBs may prevent death, kidney events in older adults after dialysis, but with caveat

ACEi/ARBs may prevent death, kidney events in older adults after dialysis, but with caveat

Ipilimumab plus nivolumab prolongs survival in melanoma with brain metastases

Ipilimumab plus nivolumab prolongs survival in melanoma with brain metastases

Zibotentan-dapagliflozin combo safe in patients with compensated cirrhosis

Zibotentan-dapagliflozin combo safe in patients with compensated cirrhosis

First-time seizures a warning signal for cancers

First-time seizures a warning signal for cancers

Asian study: Tumour multiplicity in ICC associated with inferior OS

Asian study: Tumour multiplicity in ICC associated with inferior OS

Romiplostim for chemo-induced thrombocytopenia delivers in phase 3 trial

Romiplostim for chemo-induced thrombocytopenia delivers in phase 3 trial